Table 5.

Performance of ICD-9 coding algorithms for incident heart failure or cardiomyopathy among those patients exposed to anthracycline and/or trastuzumab therapy

	ONLY EXPOSED PATIENTS	ONLY UNEXPOSED PATIENTS
	INCIDENT by Algorithm #2 (with first ICD-9 code occurring AFTER date of breast cancer diagnosis) N=29 (weighted N=7)	INCIDENT by Algorithm #2 (with first ICD-9 code occurring AFTER date of breast cancer diagnosis) N=27 (weighted N=4)
INCIDENT by gold standard (with first chart mention of HF/CM or LVEF<50% occurring BEFORE date of breast cancer diagnosis) N=32 exposed, 14 unexposed (weighted N= 5 exposed, 4 unexposed)	Sens = 57.8 (19.5–88.6) Spec = 98.1 (95.2–99.3) PPV = 42.1 (14.2–76.1) NPV =99.0 (96.3–99.7)	Sens = 19.9 (2.0–75.0) Spec = 98.0 (94.3–99.3) PPV = 18.3 (1.9–72.6) NPV = 98.2 (94.6–99.4)
INCIDENT by LVEF criteria (with first documented LVEF<50% occurring AFTER date of breast cancer diagnosis) N=28 exposed, 8 unexposed (weighted N= 4 exposed, 2 unexposed)	Sens = 55.3 (15.6–89.2) Spec = 97.8 (94.8–99.1) PPV = 33.0 (9.5–69.9) NPV =99.1 (96.5–99.8)	Sens = 4.7 (0.0–97.8) Spec = 97.6 (93.9–99.1) PPV = 2.1 (0.0–94.6) NPV = 99.0 (95.6–99.8)